Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been given an average rating of “Hold” by the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $11.71.
A number of research analysts have recently weighed in on the company. Canaccord Genuity Group increased their price target on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, July 25th. Morgan Stanley dropped their price objective on Y-mAbs Therapeutics from $7.00 to $5.00 and set an “underweight” rating for the company in a report on Monday, August 14th. JPMorgan Chase & Co. decreased their target price on Y-mAbs Therapeutics from $8.00 to $7.00 and set an “underweight” rating for the company in a research report on Tuesday, August 22nd. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Y-mAbs Therapeutics in a research report on Wednesday. Finally, Wedbush restated an “outperform” rating and set a $12.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday.
Get Our Latest Stock Report on Y-mAbs Therapeutics
Institutional Trading of Y-mAbs Therapeutics
A number of institutional investors have recently modified their holdings of YMAB. Polar Capital Holdings Plc raised its holdings in Y-mAbs Therapeutics by 108.9% during the first quarter. Polar Capital Holdings Plc now owns 2,877,671 shares of the company’s stock worth $34,187,000 after acquiring an additional 1,500,000 shares in the last quarter. Millennium Management LLC increased its position in shares of Y-mAbs Therapeutics by 4,676.0% during the 4th quarter. Millennium Management LLC now owns 1,128,702 shares of the company’s stock worth $5,508,000 after purchasing an additional 1,105,069 shares during the last quarter. State Street Corp raised its stake in shares of Y-mAbs Therapeutics by 58.5% during the 1st quarter. State Street Corp now owns 2,308,782 shares of the company’s stock worth $27,428,000 after purchasing an additional 852,112 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at approximately $2,343,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at approximately $2,193,000. 45.45% of the stock is currently owned by institutional investors.
Y-mAbs Therapeutics Price Performance
YMAB stock opened at $5.27 on Friday. The business has a fifty day moving average price of $5.27 and a 200 day moving average price of $6.43. Y-mAbs Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $10.95. The stock has a market capitalization of $229.88 million, a price-to-earnings ratio of -11.98 and a beta of 0.66.
About Y-mAbs Therapeutics
(Get Free Report
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Receive News & Ratings for Y-mAbs Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.